drugset / Trial / NCT04659070
To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is a multicenter, Randomized, double-blind, acitve-controlled, Phase 3 Clinical Trial in 8 weeks for screening, twice Investigational product administer, Follow up visit.
Timeline
- Start
- 2020-07-15
- Primary completion
- 2022-05-19
- Completion
- 2022-05-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ezetimibe | Unknown | 10 mg | Oral |
| Subject | Rosuvastatin | Small molecule | 20 mg | Oral |
| Subject | Telmisartan | Other / unclassified | 80 mg | Oral |